Workday Warns of ‘Elevated Sales Scrutiny’ in Warning for Software
(Bloomberg) -- Workday Inc. shares plunged the most in more than eight years after the software company cut its full-year forecast for subscription revenue and said customers were being more cautious with orders.
Most Read from Bloomberg
World’s Largest Nuclear Plant Sits Idle While Energy Needs Soar
‘Not Gonna Be Pretty:’ Covid-Era Homebuyers Face Huge Rate Jump
Warning Signals Are Flashing for Homeowners in Texas and Florida
Insurers Sink as UnitedHealth Sees ‘Disturbance’ in Medicaid
American Air Fired Commercial Head After Sales Strategy Alienated Corporate Clients
Subscription sales will be as much as $7.73 billion in the fiscal year ending in January, compared with an earlier outlook for as much as $7.78 billion, the Pleasanton, California-based company said Thursday. Subscription revenue is a key metric for Workday, which provides software for business tasks, such as managing personnel.
The shares fell 15% to $220.91 at the close Friday in New York, the biggest single-day decline since February 2016. The stock has dropped 20% this year.
“Our updated subscription revenue guidance reflects the elevated sales scrutiny and lower customer headcount growth we experienced during the quarter,” Chief Financial Officer Zane Rowe said in a statement.
Chief Executive Officer Carl Eschenbach, who took over as sole CEO in February, is looking for growth by expanding sales overseas and pushing into new US industries.
For the fiscal first quarter, subscription sales gained 19% to about $1.82 billion, in line with analysts’ average estimate. Profit, excluding some items, was $1.74 a share. Analysts, on average, projected $1.58, according to data compiled by Bloomberg.
“Clearly the in-line results and lowered outlook were below what investors were looking for,” wrote Kirk Materne, an analyst at Evercore ISI, in a note after the earnings were released.
(Updates with scope of share move in the first and third paragraphs.)
Most Read from Bloomberg Businessweek
Why Dave & Buster’s Is Transforming Its Arcades Into Casinos
The Secret Ozempic Recipe Behind Novo's Race to Boost Supplies
©2024 Bloomberg L.P.